Parkinson's disease: a dual-hit hypothesis

C H Hawkes, K Del Tredici, H Braak, C H Hawkes, K Del Tredici, H Braak

Abstract

Accumulating evidence suggests that sporadic Parkinson's disease has a long prodromal period during which several non-motor features develop, in particular, impairment of olfaction, vagal dysfunction and sleep disorder. Early sites of Lewy pathology are the olfactory bulb and enteric plexus of the stomach. We propose that a neurotropic pathogen, probably viral, enters the brain via two routes: (i) nasal, with anterograde progression into the temporal lobe; and (ii) gastric, secondary to swallowing of nasal secretions in saliva. These secretions might contain a neurotropic pathogen that, after penetration of the epithelial lining, could enter axons of the Meissner's plexus and, via transsynaptic transmission, reach the preganglionic parasympathetic motor neurones of the vagus nerve. This would allow retrograde transport into the medulla and, from here, into the pons and midbrain until the substantia nigra is reached and typical aspects of disease commence. Evidence for this theory from the perspective of olfactory and autonomic dysfunction is reviewed, and the possible routes of pathogenic invasion are considered. It is concluded that the most parsimonious explanation for the initial events of sporadic Parkinson's disease is pathogenic access to the brain through the stomach and nose - hence the term 'dual-hit'.

Figures

Figure 1
Figure 1
(A–B, left hand side) to illustrate the mode of spread of herpes simplex virus following injection into peripheral portions of the vagus nerve in the rat medulla oblongata, adapted and reproduced in part with permission from Blessing et al.[154]. (A–B, right hand side) to show the topographical distribution pattern of α‐synuclein pathology in the human medulla in stages 1 and 2 of sporadic Parkinson's disease, adapted and reproduced in part with permission from Del Tredici et al.[21]. amb, ambiguus nucleus; dmo, dorsal motor nucleus of the vagus (marked in green); gig, gigantocellular reticular nucleus, iop, inferior olivary nucleus, principal subnucleus; irz, intermediate reticular zone; rob, nucleus raphes obscurus; sol, solitary tract; XII, motor nucleus of the hypoglossal nerve.
Figure 2
Figure 2
Alpha‐synuclein immunoreactions (Syn‐1: 1:2 000, Transduction Laboratories) in 6‐μm paraffin sections showing Lewy bodies (A, arrows and B) in the Auerbach plexus of the human oesophagus. Scale bar in (B) is valid for (A). Reproduced in part with permission from Braak et al. [24]. Aggregated axonal α‐synuclein inclusions (Lewy neurites) in the gastric Meissner plexus (C,D). Notice how the terminal ramifications of abnormally altered axons extend through the lamina propria of the gastric mucosa and run parallel to the gastric glands (D). Syn‐1 immunoreactions in 150‐μm cryosections. Scale bar in (D) also applies to (C). Adapted and reproduced with permission from Braak et al. [88].
Figure 3
Figure 3
Simplified diagram showing the vagal interconnections between the enteric nervous system and medulla oblongata. A neurotropic agent capable of passing through the mucosal epithelial barrier of the stomach could enter terminal axons of postganglionic VIPergic neurones (black, rounded cell somata) in the submucosal Meissner plexus and, via retrograde axonal and transneuronal transport (black, rounded cell somata in the Auerbach plexus), reach the preganglionic cholinergic neurones (black, diamond‐shaped cell somata) of the dorsal motor nucleus of the vagus in the lower brainstem. Reproduced with permission from Braak et al. [88].
Figure 4
Figure 4
Two schematic drawings. (A) The essentially caudal‐rostral expansion (white arrows) of the Lewy body pathology in the brain after it attains a foothold in the dorsal motor nucleus of the vagus in the medulla oblongata (here, in black). The other consistently involved induction site in sporadic Parkinson's disease is the olfactory bulb (black). Reproduced with permission from Braak et al. [22]. (B) Median view of a mediosagittal section through the human brain: lines A and B indicate the respective planes of the frontal sections through the medulla oblongata depicted in Figure 1. Adapted and reproduced in part with permission from Del Tredici et al. [21].

References

    1. Hague K, Lento P, Morgello S, Caro S, Kaufmann H. The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol 1997; 94: 92–6
    1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol 1999; 56: 33–9
    1. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003; 18 (Suppl. 6): 2–12
    1. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I. SIC Task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003; 18: 467–86
    1. Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 2005; 20 (Suppl. 12): 11–20
    1. Lowe J. Lewy bodies In Neurodegenerative Diseases. Ed. Calne DP. Philadelphia, PA: Saunders, 1994; 51–69
    1. Duda JE, Lee VMY, Trojanowski JQ. Neuropathology of synuclein aggregates: new insights into mechanism of neurodegenerative diseases. J Neurosci Res 2000; 61: 121–7
    1. Del Tredici K, Braak H. Idiopathic Parkinson's disease: staging an α‐synucleinopathy with a predictable pathoanatomy In Molecular Mechanisms in Parkinson's Disease. Eds Kahle P, Haass C. Georgetown, TX: Landes Bioscience, 2004; 1–32
    1. Jellinger K. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991; 14: 153–97
    1. Takahashi H, Wakabayashi K. The cellular pathology of Parkinson's disease. Neuropathology 2001; 21: 315–22
    1. Takahashi H, Wakabayashi K. Controversy: is Parkinson's disease a single disease entity? Yes. Parkinsonism Relat Disord 2005; 11: 31–7
    1. Braak H, Del Tredici K. Preclinical and clinical stages of intracerebral inclusion body pathology in idiopathic Parkinson's disease In Parkinson's Disease: Progress in Research. Ed. Willow. JM. Hauppauge, NY: Nova Science, 2005; 1–49
    1. Braak H, Del Tredici K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 2004; 25: 19–23
    1. Thal DR, Del Tredici K, Braak H. Neurodegeneration in normal brain aging and disease. Sci Aging Knowledge Environ 2004; 23: 1–13
    1. Mikolaenko I, Pletnikova O, Kawas CH, O'Brien R, Resnick SM, Crain B, Troncosco JC. Alpha‐synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol 2005; 64: 156–62
    1. Foley P, Riederer P. Pathogenesis and preclinical course of Parkinson's disease. J Neural Transm Suppl 1999; 56: 31–74
    1. Wolters EC, Francot C, Bergmans P, Winogrodzka A, Booij J, Berendse HW, Stoof JC. Preclinical premotor; Parkinson's disease. J Neurol 2000; 247 (Suppl. 2): 103–9
    1. Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm 2004; 111: 201–16
    1. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745–52
    1. Hawkes CH, Shephard BC, Daniel SE. Is Parkinson's disease a primary olfactory disorder? Q J Med 1999; 92: 473–80
    1. Del Tredici K, Rüb U, de Vos RAI, Bohl JRE, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002; 61: 413–26
    1. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197–211
    1. Braak H, Rüb U, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003; 110: 517–36
    1. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease‐related pathology. Cell Tissue Res 2004; 318: 121–34
    1. Braak H, Müller CM, Rüb U, Ackermann H, Bratzke H, de Vos RAI, Del Tredici K. Pathology associated with sporadic Parkinson's disease – where does it end? J Neural Transm Suppl 2006; 70: 89–97
    1. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004; 3: 309–16
    1. Ahlskog JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov Disord 2005; 20: 271–82
    1. Langston JW. The Parkinson's complex: Parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59: 591–6
    1. Ansari KA, Johnson A. Olfactory function in patients with Parkinson's disease. J Chronic Dis 1975; 28: 493–7
    1. Quinn NP, Rossor MN, Marsden CD. Olfactory threshold in Parkinson's disease. J Neurol Neurosurg Psychiatry 1987; 50: 88–9
    1. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988; 38: 1237–44
    1. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 138–42
    1. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 436–46
    1. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. ‘Sniffin sticks’: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 1997; 22: 39–52
    1. Daum RF, Sekinger B, Kobal G, Lang CJ. Olfactory testing with ‘sniffin’ sticks' for clinical diagnosis of Parkinson's disease. Nervenarzt 2000; 71: 643–50
    1. Liberini P, Parola S, Spano PF, Antonini I. Olfaction in Parkinson's disease: methods of assessment and clinical relevance. J Neurol 2000; 247: 88–96
    1. Hawkes CH. Olfaction in neurodegenerative disorder. Mov Disord 2003; 18: 364–72
    1. Doty RL. Olfaction. Annu Rev Psychol 2001; 52: 423–52
    1. Katzenschlager R, Lees AJ. Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr Opin Neurol 2004; 17: 417–23
    1. Kobal G, Plattig KH. Objective olfactometry: methodological annotations for recording olfactory EEG‐responses from the awake human. EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb 1978; 9: 135–45
    1. Barz S, Hummel T, Pauli E, Majer M, Lang CJ, Kobal G. Chemosensory event‐related potentials in response to trigeminal and olfactory stimulation in idiopathic Parkinson's disease. Neurology 1997; 49: 1424–31
    1. Tissingh G, Berendse HW, Bergmanns P, De Waard R, Drukarch B, Stoof JC, Wolters EC. Loss of olfaction in de novo and treated Parkinson's disease: possible implication for early diagnosis. Mov Disord 2001; 16: 41–6
    1. Montgomery EB Jr, Baker KB, Lyons K, Koller WC. Abnormal performance on the PD test battery by asymptomatic first‐degree relatives. Neurology 1999; 52: 757–62
    1. Montgomery EB Jr, Lyons K, Koller WC. Early detection of probable idiopathic Parkinson's disease: II. A prospective application of a diagnostic test battery. Mov Disord 2000; 15: 474–8
    1. Ponsen MM, Stoffers D, Booij J, van Eck‐Smit BL, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56: 173–81
    1. Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H. Detection of presymptomatic Parkinson's disease. combining smell tests transcranial sonography and SPECT. Mov Disord 2004; 19: 1196–202
    1. Ross W, Petrovitch H, Abbott RD, Tanner CM, Popper Masaki K. Association of olfactory dysfunction with risk of future Parkinson's disease. Mov Disord 2005; 20 (Suppl. 10): 439
    1. Doty RL, Marcus A, Lee WW. Development of the 12‐item cross‐cultural smell identification test CC‐SIT. Laryngoscope 1996; 106: 353–6
    1. Ross GW, Abbott RD, Petrovitch H, Tanner CM, Davis DG, Nelson J, Markesbery WR, Hardman J, Masaki K, Launer L, White LR. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 2006; 21: 2062–7
    1. Marras C, Goldman S, Smith A, Barney P, Aston D, Comyns K, Korell M, Langston JW, Ross GW, Tanner CM. Smell identification ability in twin pairs discordant for Parkinson's disease. Mov Disord 2005; 20: 687–93
    1. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497–9
    1. Jost WH. Autonomic dysfunctions in idiopathic Parkinson's disease. J Neurol 2003; 250 (Suppl. 1): 28–30
    1. Micieli G, Tosi P, Marcheselli S, Cavallini A. Autonomic dysfunction in Parkinson's disease. Neurol Sci 2003; 24: 32–4
    1. Visser M, Marinus J, Stiggelbout AM, van Hilten J. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA‐AUT. Mov Disord 2004; 19: 1306–12
    1. Goetze O, Wieczorek J, Mueller T, Przuntek H, Schmidt WE, Woitalla D. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C‐sodium octanoate breadth test. Neurosci Lett 2005; 375: 170–3
    1. Bine JE, Frank EM, McDade HL. Dysphagia and dementia in subjects with Parkinson's disease. Dysphagia 1995; 10: 160–4
    1. Muller J, Wenning GK, Verny M, McKee A, Chaudhuri KR, Jellinger K. Progression of dysarthria and dysphagia in postmortem‐confirmed parkinsonian disorders. Arch Neurol 2001; 58: 259–64
    1. Hawkes CH. Smell and Taste Complaints. Boston, MA: Butterworth‐Heinemann/Elsevier, 2002.
    1. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003; 2: 107–16
    1. Tumilasci OR, Cersosimo MG, Belforte JE, Micheli FE, Benarroch EE, Pazo JH. Quantitative study of salivary secretion in Parkinson's disease. Mov Disord 2006; 21: 660–7
    1. Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992; 42: 726–32
    1. Hardoff R, Sula M, Tamir A, Soil A, Front A, Badarna S. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 2001; 16: 1041–7
    1. Sulla M, Hardoff R, Giladi N. Gastric emptying time and gastric motility in patients with untreated Parkinson's disease. Mov Disord 1996; 11: 1041–7
    1. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001; 57: 456–62
    1. Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF. Autonomic dysfunction in Parkinson's disease: a comprehensive symptom survey. Parkinsonism Relat Disord 2002; 8: 277–84
    1. Jost WH, Jung G, Schimrigk K. Colonic transit time in non–idiopathic Parkinson's syndrome. Eur Neurol 1994; 34: 329–31
    1. Jost WH, Schrank B. Defecatory disorders in de novo Parkinsonians – colonic transit and electromyogram of the external anal sphincter. Wien Klin Wochenschr 1998; 110: 535–7
    1. Iwasa K, Nakajima K, Yoshikawa H, Tada A, Taki J, Takamori M. Decreased myocardial 123I‐MIBG uptake in Parkinson's disease. Acta Neurol Scand 1998; 97: 303–6
    1. Satoh A, Serita T, Seto M, Tomita I, Satoh H, Iwanaga K, Takashima H, Tsujihata M. Loss of 123I‐MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 1999; 40: 371–5
    1. Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon RO. Cardiac sympathetic denervation in Parkinson's disease. Ann Intern Med 2000; 133: 338–47
    1. Takatsu H, Nishida H, Matsuo H, Watanabe S, Nagashima K, Wada H, Noda T, Nishigaki K, Fujiwara H. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 2000; 41: 71–7
    1. Taki J, Yoshita M, Yamada M, Tonami N. Significance of 123I‐MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med 2004; 18: 453–61
    1. Haapaniemi TH, Pursiainen V, Korpelainen JT, Huikuri HV, Sotaniemi KA, Myllyla VV. Ambulatory ECG and analysis of heart rate variability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70: 305–10
    1. Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H. Lewy body‐type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 1999; 52: 1269–71
    1. Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T, Tsuchiya K, Mori F, Wakabayashi K, Takahashi H. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol (Berl) 2005; 109: 583–8
    1. Kaufmann H, Nahm K, Purohit D, Wolfe D. Autonomic failure as the initial manifestation of Parkinson's disease and dementia with Lewy bodies. Neurology 2004; 63: 1093–5
    1. Lee PH, Yeo SH, Kim HJ, Youm HY. Correlation between cardiac 123I‐MIBG and odor identification in patients with Parkinson's disease and multiple system atrophy. Mov Disord 2006; 21: 1975–7
    1. Adler CH, Thorpy MJ. Sleep issues in Parkinson's disease. Neurology 2005; 64 (Suppl. 3): 12–20
    1. Schenck CH, Bundlie SR, Mahowald MW. REM behavior disorder (RBD), delayed emergence of parkinsonism and/or dementia in 65% of older men initially diagnosed with idiopathic RBD, and an analysis of the minimum & maximum tonic and/or phasic electromyographic abnormalities found during REM sleep. Sleep 2003; 26 (Suppl.): 316 [Abs 0794.M; A316]
    1. Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, Parisi JE, Benarroch EE, Ahlskog JE, Smith GE, Caselli RC, Tippman‐Peikert M, Olson EJ, Lin SC, Young T, Wszolek Z, Schenck CH, Mahowald MW, Castillo PR, Del Tredici K, Braak H. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007; doi: 10.1093/brain/awm056
    1. Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, Curb JD, Petrovitch H. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005; 65: 1442–6
    1. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46: 388–93
    1. Eisensehr I, Linke R, Tatsch K, Kharraz B, Gildehaus JF, Wetter CT, Trenkwalder C, Schwarz J, Noachtar S. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep 2003; 26: 507–12
    1. Stiasny‐Kolster K, Doerr Y, Möller JC, Hoffken H, Behr TM, Oertel WH, Mayer G. Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α‐synucleinopathy demonstrated by dopamine transporter FP‐CIT‐SPECT. Brain 2005; 128: 126–37
    1. Postuma RB, Lang AE, Massicotte‐Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006; 66: 845–51
    1. Fantini ML, Postuma RB, Montplaisir J, Ferini‐Strambi L. Olfactory deficit in idiopathic rapid eye movements sleep behavior disorder. Brain Res Bull 2006; 70: 386–90
    1. Iranzo A, Santamaria J, Rye DB, Valldeoriola F, Marti MJ, Munoz E. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 2005; 65: 247–52
    1. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric alpha‐synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease‐related brain pathology. Neurosci Lett 2006; 396: 67–72
    1. Braak H, Sastre M, Bohl JRE, de Vos RAI, Del Tredici K. Parkinson's disease: Lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre‐ and postganglionic neurons. Acta Neuropathol 2007; 113: 421–9
    1. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen ENH, Bohl J, Jellinger K. Amygdala pathology in Parkinson's disease. Acta Neuropathol 1994; 88: 493–500
    1. Bohus B, Koolhaas JM, Luiten PGM, Korte SM, Roozendaal B, Wiersma A. The neurobiology of the central nucleus of the amygdala in relation to neuroendocrine and autonomic outflow. Prog Brain Res 1996; 107: 447–60
    1. Liubashima O, Jolkkonen E, Pitkänen A. Projections from the central nucleus of the amygdala to the gastric related area of the dorsal vagal complex: a Phaseolus vulgaris leucoagglutinin study in rat. Neurosci Lett 2000; 291: 85–8
    1. Zhang X, Cui J, Tan Z, Jiang C, Fogel R. The central nucleus of the amygdala modulates gut‐related neurons in the dorsal vagal complex in rats. J Physiol 2003; 553: 1005–18
    1. Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I. α‐Synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005; 57: 82–91
    1. Jellinger KA. Lewy body‐related alpha‐synucleinopathy in the aged human brain. J Neural Transm 2004; 111: 1219–35
    1. Neumann M, Müller V, Kretzschmar HA, Haass C, Kahle PJ. Regional distribution of proteinase‐K‐resistent α‐synuclein correlates with Lewy body disease stage. Neuropathol Exp Neurol 2004; 63: 1225–35
    1. Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, Hosoi T, Yamanouchi H, Murayami S. Lewy body‐related alpha‐synucleinopathy in aging. J Neuropathol Exp Neurol 2004; 63: 742–9
    1. Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amgydala Lewy bodies: a distinct form of alpha‐synucleinopathy. J Neuropathol Exp Neurol 2006; 65: 685–97
    1. Müller CM, de Vos RAI, Maurage CA, Thal DR, Tolnay M, Braak H. Staging of sporadic Parkinson disease‐related alpha‐synuclein pathology: inter‐ and intra‐rater reliability. J Neuropathol Exp Neurol 2005; 64: 623–8
    1. Duda JE, Shah U, Arnold SE, Lee VM, Trojanowski JQ. The expression of alpha‐, beta‐, and gamma‐synucleins in olfactory mucosa from patients with and without neurodegenerative diseases. Exp Neurol 1999; 160: 515–22
    1. Witt M, Gudziol V, Haehner A, Reichmann H, Hummel T. Nasal mucosa in patients with Parkinson's disease. Chem Senses 2006; 31: 479–93 (Abstract 106)
    1. Daniel SE, Hawkes CH. Preliminary diagnosis of Parkinson's disease by olfactory bulb pathology. Lancet 1992; 340: 186
    1. Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson's disease. Mov Disord 1995; 10: 283–7
    1. Huisman E, Uylings HB, Hoogland PV. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease. Mov Disord 2004; 19: 687–92
    1. Price JL. Olfaction In The Human Nervous System, 2nd edn Eds Paxinos G, Mai. JM. San Diego, CA: Elsevier Academic Press, 2004; 1198–212
    1. Jager W, den Hartog WA, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous system in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 1960; 23: 283–90
    1. Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterol 1984; 87: 848–56
    1. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997b; 38 (Suppl. 2): 2–7
    1. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body‐containing neurons in the enteric nervous system. Acta Neuropathol 1990; 79: 581–3
    1. Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Adv Neurol 1993; 60: 609–12
    1. Costa M, Brookes SJH, Hennig GW. Anatomy and physiology of the enteric nervous system. Gut 2000; 47 (Suppl. 4): iv15–19
    1. Furness JB. Types of neurons in the enteric nervous system. J Auton Nerv Syst 2000; 81: 87–96
    1. Anlauf M, Schäfer MKH, Eiden L, Weihe E. Chemical coding of the human gastrointestinal nervous system: cholinergic, VIPergic, and catecholaminergic phenotypes. J Comp Neurol 2003; 459: 90–111
    1. Huang XF, Törk I, Paxinos G. Dorsal motor nucleus of the vagus nerve: a cyto‐ and chemoarchitectonic study in the human. J Comp Neurol 1993; 330: 158–82
    1. Hopkins DA, Bieger D, de Vente J, Steinbusch HWM. Vagal efferent projections: viscerotopy, neurochemistry and effects of vagotomy. Prog Brain Res 1996; 107: 79–96
    1. Huang XF, Paxinos G. Human intermediate reticular zone: a cyto‐ and chemoarchitectonic study. J Comp Neurol 1995, 2004; 360: 571–88
    1. Blessing WW. Lower brain stem regulation of visceral, cardiovascular, and respiratory function In The Human Nervous System, 2nd edn Eds Paxinos G, Mai JK. San Diego, CA: Elsevier Academic Press, 2004; 464–78
    1. Wakabayashi K, Takahashi H. The intermediolateral nucleus and Clarke's column in Parkinson's disease. Acta Neuropathol 1997a; 94: 287–9
    1. Bloch A, Probst A, Bissig H, Adams H, Tolnay M. α‐Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 2006; 12: 284–95
    1. Klos KJ, Ahlskog JE, Josephs KA, Apaydin H, Parisi JE, Boeve BF. Alpha‐synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 2006; 66: 1100–2
    1. Pearson RCA, Esiri MM, Hiorns RW, Wilcock GK, Powell TPS. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer's disease. Proc Natl Acad Sci USA 1985; 82: 4531–4
    1. Saper CB, Wainer BH, German DC. Axonal and transneuronal transport in the transmission of neurological disease: potential role in system degenerations, including Alzheimer's disease. Neuroscience 1987; 23: 389–98
    1. Kristensson K. Sorting signals and targeting of infectious agents through axons: an annotation to the 100 years' birth of the name ‘axon’. Brain Res Bull 1996; 41: 327–33
    1. Pearson RCA. Cortical connections and the pathology of Alzheimer's disease. Neurodegeneration 1996; 5: 429–34
    1. Card JP. Exploring brain circuitry with neurotropic viruses: new horizons in neuroanatomy. Anat Rec 1998; 253: 176–85
    1. Mufson EJ, Kroin JS, Sendera TJ, Sobreviela T. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 1999; 57: 451–84
    1. Rinaman L, Levitt P, Card JP. Progressive postnatal assembly of limbic‐autonomic circuits revealed by central transneuronal transport of pseudorabies virus. J Neurosci 2000; 20: 2731–41
    1. Nicotera P. A route for prion neuroinvasion. Neuron 2001; 31: 345–8
    1. Hill TJ. Ocular pathogenicity of herpes simplex virus. Curr Eye Res 1987; 6: 1–7
    1. Morrison LA, Sidman RL, Fields BN. Direct spread of reovirus from the intestinal lumen to the central nervous system through vagal autonomic nerve fibers. Proc Natl Acad Sci USA 1991; 88: 3852–6
    1. Enquist LW, Card JP. Recent advances in the use of neurotropic viruses for circuit analysis. Curr Opin Neurobiol 2003; 13: 603–6
    1. Matsuda K, Park CH, Synden Y, Kimura T, Ochiai K, Kida H. The vagus nerve is one route of transneural invasion for intranasally inoculated influenza A virus in mice. Vet Pathol 2004; 41: 101–7
    1. Broadwell RD, Brightman MV. Entry of peroxidase into neurons of the central and peripheral nervous systems from extracerebral and cerebral blood. J Comp Neurol 1976; 166: 257–84
    1. Elizan TS, Casals J. The viral hypothesis in parkinsonism. J Neural Transm Suppl 1983; 19: 75–88
    1. Ahlskog JE, Waring SC, Petersen RC, Esteban‐Santillan C, Craig UK, O'Brien PC, Plevak MF, Kurland LT. Olfactory dysfunction in Guamanian ALS, parkinsonism, and dementia. Neurology 1998; 51: 1672–7
    1. Takahashi M, Yamada T. A possible role of influenza A virus infection for Parkinson's disease. Adv Neurol 2001; 86: 91–104
    1. Gamboa ET, Wolf A, Yahr MD, Harter DH, Duffy PE, Barden H, Hsu KC. Influenza virus antigen in postencephalitic parkinsonism brain. Arch Neurol 1974; 31: 228–32
    1. Marttila RJ, Halonen P, Rinne UK. Influenza virus antibodies in Parkinsonism. Comparison of postencephalic and idiopathic Parkinson patients and matched controls. Arch Neurol 1977; 34: 99–100
    1. Elizan TS, Madden DL, Noble GR, Herrmann KL, Gardner J, Schwartz J, Smith H, Sever JL, Yahr MD. Viral antibodies in serum and CSF of parkinsonian patients and controls. Arch Neurol 1979; 36: 529–34
    1. Schwartz J, Elizan TS. Search for viral particles and virus‐specific products in idiopathic Parkinson disease brain material. Ann Neurol 1979; 6: 261–3
    1. Wetmur JG, Schwartz J, Elizan TS. Nucleic acid homology studies of viral nucleic acids in idiopathic Parkinson's disease. Arch Neurol 1979; 36: 462–4
    1. Solbrig MV, Nashef L. Acute parkinsonism in suspected herpes simplex encephalitis. Mov Disord 1993; 8: 233–4
    1. Howard JS. Tic douloureux, Parkinson's disease and the herpes connection. Integr Physiol Behav Sci 1997; 32: 257–64
    1. Marttila RJ, Rinne UK, Halonen P, Madden DL, Sever JL. Herpesviruses and Parkinsonism. Herpes simplex virus types 1 and 2, and cytomegalovirus antibodies in serum and CSF. Arch Neurol 1981; 38: 19–21
    1. Marttila RJ, Rinne UK, Tilikainen A. Virus antibodies in Parkinson's disease. J Neurol Sci 1982; 54: 227–38
    1. Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease. Mov Disord 1992; 7: 153–8
    1. Bower JH, Maraganore DM, Peterson BJ, Ahlskog JE, Rocca WA. Immunologic diseases, anti‐inflammatory drugs, and Parkinson disease: a case‐control study. Neurology 2006; 67: 494–6
    1. Klimek L. Sense of smell in allergic rhinitis. Pneumologie 1998; 52: 196–202
    1. Masucci MG. Epstein‐Barr virus oncogenesis and the ubiquitin‐proteasome system. Oncogene 2004; 23: 2107–15
    1. Shackelford J, Pagano JS. Targeting of host‐cell ubiquitin pathways by viruses. Essays Biochem 2005; 41: 139–56
    1. Tomlinson AH, Esiri MM. Herpes simplex encephalitis: immuno‐histological demonstration of spread of virus via olfactory pathways in mice. J Neurol Sci 1983; 60: 473–84
    1. Shipley MT. Transport of molecules from nose to brain: transneuronal anterograde and retrograde labelling in the rat olfactory system by wheatgerm agglutin‐horseradish peroxidase applied to the nasal epithelium. Brain Res Bull 1985; 15: 129–42
    1. Newman R, Winans SS. An experimental study of the ventral striatum of the golden hamster. II. Neuronal connections of the olfactory tubercle. J Comp Neurol 1980; 191: 193–212
    1. Blessing WW, Li YW, Wesselingh SL. Transneuronal transport of herpes simplex virus from the cervical vagus to brain neurons with axonal inputs to central vagal sensory nuclei in the rat. Neuroscience 1991; 42: 261–74
    1. Park CH, Ishinaka M, Takada A, Kida H, Kimura T, Ochiai K, Umimura T. The invasion routes of neurovirulent A/Hong Kong/483/97, H5N1; influenza virus into the central nervous system after respiratory infection in mice. Arch Virol 2002; 147: 1425–36
    1. Shinya K, Shimada A, Ito T, Otsuki K, Morita T, Tanaka H, Takada A, Kida H, Umemura T. Avian influenza virus intranasally inoculated infects the central nervous system of mice through the general visceral afferent nerve. Arch Virol 2000; 145: 187–95
    1. Halliday G, Del Tredici K, Braak H. Critical appraisal of the Braak staging of brain. pathology related to sporadic Parkinson's disease. J Neural Transm (Suppl) 2006; 70: 99–103

Source: PubMed

3
Sottoscrivi